Last reviewed · How we verify
NCT02294162
Pain Relief for Submucosal Resection of Nasal Septum in Adults Does Ketamine Have a Pre-Emptive Effect?
NA trial testing Ketamine i.v in Nasal Obstruction. Withdrawn.
1 October 2017
Quick facts
| Lead sponsor | Western Galilee Hospital-Nahariya |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Start date | 1 April 2015 |
| Primary completion | 1 October 2017 |
| Estimated completion | 1 October 2017 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Ketamine i.v — full drug profile →
Conditions studied
- Nasal Obstruction — all drugs for Nasal Obstruction →
Sponsor
Western Galilee Hospital-Nahariya
Who can join
Adults 18 to 100, any sex, with Nasal Obstruction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pain is an unpleasant sensory experience associated with actual or potential tissue damage. Acute pain management is an important aspect of perioperative anesthetic care. Moreover, it is the most important factor related to patient discomfort after surgery. Adequate pain management, ideally resulting in the complete absence of postoperative pain, not only provides comfort to patients, but may also contribute to improved healing and a reduction in the incidence of postoperative complications. Inadequate postoperative analgesia has been shown to contribute to adverse outcomes, including, but not limited to, immunosuppression, hyperglycemia, poor rehabilitation, and progression to chronic pain.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02294162
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nasal Obstruction
Currently open trials in the same condition.
- NCT06580210 — Performance and Safety Assessment of the Mechanical Decongestant Seawater Spray Enriched With Essential Oils From Labora · recruiting
- NCT06830109 — Nasal Obstruction With Oxymetazoline and Corticosteroids · Phase 2 · recruiting
- NCT06670261 — Diagnosis of Respiratory Disorders by the Numerical Modeling. · recruiting
- NCT05494346 — Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patien · NA · recruiting
- NCT05920330 — Nasal Obstruction and Olfactory Losses · NA · recruiting
Other Western Galilee Hospital-Nahariya trials
Trials by the same sponsor.
- NCT07536425 — Preoperative Indomethacin and Paracetamol for Pain Management During Oocyte Retrieval in IVF Patients · Phase 4 · not yet recruiting
- NCT07353281 — Carbetocin vs Misoprostol for Postpartum Hemorrhage Prevention · NA · not yet recruiting
- NCT07317674 — Combined Nipple Stimulation and Foley Balloon for Cervical Ripening · NA · not yet recruiting
- NCT06578754 — Validation Testing for Plasma Oxalate Levels in the Biochemical Laboratory at the Galilee Medical Center, in Collaborati · not yet recruiting
- NCT07311395 — Local Subcutaneous Gentamicin for Prevention of Surgical Site Infection After Elective Cesarean Section · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02294162 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Western Galilee Hospital-Nahariya
- Last refreshed: 3 October 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02294162.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing